• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $NAUT

    Nautilus Biotechnolgy Inc.

    Subscribe to $NAUT
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the human proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company is headquartered in Seattle, Washington.

    IPO Year: 2020

    Exchange: NASDAQ

    Website: nautilus.bio

    Peers

    $NLS

    Recent Analyst Ratings for Nautilus Biotechnolgy Inc.

    DatePrice TargetRatingAnalyst
    12/5/2024$1.75Neutral → Sell
    Goldman
    6/27/2024$6.00Buy
    Guggenheim
    6/3/2024$3.00Hold
    Jefferies
    1/6/2022$8.00Equal-Weight
    Morgan Stanley
    11/2/2021Outperform
    Cowen & Co.
    8/4/2021$10.00Neutral
    Goldman Sachs
    7/13/2021$13.00Buy
    Jefferies
    See more ratings

    Nautilus Biotechnolgy Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Nautilus Biotechnology Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer

      SEATTLE, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform for comprehensively quantifying the proteome, today announced the appointment of Kentaro (Ken) Suzuki as Chief Marketing Officer. Mr. Suzuki joins Nautilus after 25 years in product and marketing leadership roles at Agilent Technologies, most recently serving as Vice President and General Manager of Agilent's Mass Spectrometry division. He has held numerous leadership positions at Agilent, including in the Strategic Program Office and Certified Pre-Owned Instruments, CrossLab Services and Support, and Spectroscopy. "Ke

      9/17/24 8:00:00 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Nautilus Biotechnology Appoints Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development

      SEATTLE, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the expansion of its research and development senior leadership team with the appointment of Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development. Dr. Huber brings to Nautilus over 20 years of experience in biotechnology start-ups both in Europe and the US, most recently as founder, CTO and, ultimately, CEO of Quantapore, a company devoted to pioneering massively parallel, direct, single-molecule DNA and protein analytical tools. Prior to that, he he

      11/1/23 8:05:00 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Nautilus Biotechnology Appoints Eric Spence as Vice President of Instrument Engineering and Ken Kuhn, Ph.D., as Vice President of Reagent and Platform Development

      SEATTLE, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced further expansion of its management team with the appointments of Eric Spence as Vice President of Instrument Engineering and Ken Kuhn, Ph.D., as Vice President of Reagent and Platform Development. Both executives join the company's product development team. Eric Spence, Vice President of Instrument Engineering: Instrument engineering veteran Eric Spence comes to Nautilus from Genapsys, where he advanced through several positions of increasing responsibility leading the instrum

      8/1/22 4:05:00 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Nautilus Biotechnology Appoints Gwen Weld as Chief People Officer and Sheri Wilcox, Ph.D., as Vice President of Affinity Reagent Development

      SEATTLE, April 12, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the appointments of Gwen Weld as Chief People Officer and Sheri Wilcox, Ph.D., as Vice President of Affinity Reagent Development, adding further experience to its senior leadership team in its ongoing expansion of the organization. Gwen Weld, Chief People Officer Gwen Weld brings to Nautilus more than 25 years of senior leadership in human resources, organizational culture, and business strategy. Immediately prior to joining the company, Ms. Weld served as Interim Chief Peopl

      4/12/22 8:00:00 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Nautilus Biotechnology Appoints Karen Akinsanya, Ph.D., to Board of Directors

      SEATTLE, March 31, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the appointment of Karen Akinsanya, Ph.D., to its Board of Directors. Dr. Akinsanya brings more than 25 years of experience in drug discovery and development, commercialization, partnerships, and licensing from across academia and pharmaceutical research and development (R&D). In her current role as President of R&D, Therapeutics at Schrödinger, she leads the company's therapeutics group that leverages Schrödinger's leading physics-based platform for preclinical drug discovery

      3/31/22 4:05:00 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Nautilus Biotechnology Appoints Karl Voss, Ph.D., as Vice President of Life Sciences Research and Development

      SEATTLE, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the appointment of Karl Voss, Ph.D., as Vice President of Life Sciences Research and Development. He and his team will work out of Nautilus' research headquarters in San Carlos, California. Dr. Voss brings more than 20 years of experience directing single-molecule biophysics and biochemistry, cell biology, and materials science research at leading biotechnology and life sciences companies. He was previously Vice President of Consumables Research and Development at Pacific Biosc

      8/9/21 8:00:00 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    Nautilus Biotechnolgy Inc. Financials

    Live finance-specific insights

    See more
    • Nautilus Biotechnology Reports First Quarter 2025 Financial Results

      SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2025. "In Q1, we saw continued development progress based on the results of internal verification and validation work we've done on our Tau proteoform assay," said Sujal Patel, CEO of Nautilus Biotechnology. "The assay's reproducibility, accuracy, dynamic range, and sample compatibility align closely with our anticipated launch specifications and with the requirements we continue to hear from potential customers and partners. We are confident that 202

      4/29/25 8:00:00 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Nautilus Biotechnology to Announce First Quarter 2025 Financial Results on April 29, 2025

      SEATTLE, April 16, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule proteome analysis platform, today announced it will report financial results for the first quarter 2025 before market open on Tuesday, April 29, 2025. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle, Washington and it

      4/16/25 8:00:00 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2024 Financial Results

      SEATTLE, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2024. Reported total operating expenses for the fourth quarter of 2024 were $20.0 million, roughly equal to the fourth quarter of 2023, and $0.9 million above last quarter reflecting an ongoing focus on expense management;Announced an expectation that the launch of Nautilus' proteome analysis platform - instruments and reagents - will occur in late 2026;Announced a reduction in headcount of approximately 16% in order to appropriat

      2/27/25 8:00:00 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

      SEATTLE, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the fourth quarter and full year of 2024 before market open on Thursday, February 27, 2025. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattl

      2/6/25 8:00:00 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Nautilus Biotechnology Reports Third Quarter 2024 Financial Results

      SEATTLE, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2024. "I'm excited about the expanding opportunity I see for proteomics and am pleased with the progress we're making as a business," said Sujal Patel, CEO of Nautilus. "We consistently receive positive feedback from researchers around the world as they tell us of their desire to explore the proteome more deeply and more broadly, and of the significant limitations of what's currently available. It is becoming ever more apparent that they understand

      10/29/24 8:00:00 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Nautilus Biotechnology to Announce Third Quarter 2024 Financial Results on October 29, 2024

      SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the third quarter 2024 before market open on Tuesday, October 29, 2024. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle, Washington and i

      10/8/24 8:00:00 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Nautilus Biotechnology Reports Second Quarter 2024 Financial Results

      SEATTLE, July 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2024. "In Q2, we saw continued progress against core development goals for each of the components of our platform," said Sujal Patel, CEO of Nautilus. "We believe we are pioneering a fundamentally new approach that holds the potential to overcome the limitations of traditional and peptide-based protein analysis methods and to unlock the value of the proteome – both in targeted proteoform analysis and broadscale discovery – something we continue to vie

      7/30/24 8:00:00 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Nautilus Biotechnology to Announce Second Quarter 2024 Financial Results on July 30, 2024

      SEATTLE, July 09, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the second quarter 2024 before market open on Tuesday, July 30, 2024. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle, Washington and its

      7/9/24 8:00:00 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Nautilus Biotechnology Reports First Quarter 2024 Financial Results

      SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2024. "We continued to make solid progress against our core development goals in Q1," said Sujal Patel, CEO of Nautilus.   "We remain incredibly focused on increasing the scale, stability, and reproducibility of our consumables, assay, instrument, and software and continue to see meaningful gains along each of those dimensions. We are clear-eyed about what work remains to be done and confident that we have a foundational understanding of what is requ

      4/30/24 8:00:00 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Nautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024

      SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the first quarter 2024 before market open on Tuesday, April 30, 2024. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle, Washington and it

      4/11/24 8:00:00 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    Nautilus Biotechnolgy Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO, President, and Secretary Patel Sujal M bought $76,918 worth of shares (77,233 units at $1.00), increasing direct ownership by 0.77% to 10,141,721 units (SEC Form 4)

      4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

      3/21/25 4:44:37 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4 filed by General Counsel Murphy Matthew B.

      4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

      3/4/25 4:52:51 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4 filed by CFO and Treasurer Mowry Anna

      4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

      3/4/25 4:52:41 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4 filed by CBO & Senior VP, Bus. Dev. Nelson Nicholas A.

      4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

      3/4/25 4:52:28 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4 filed by Chief People Officer Weld Gwen E

      4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

      3/4/25 4:52:15 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4 filed by Chief Marketing Officer Suzuki Kentaro

      4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

      3/4/25 4:52:04 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4 filed by Chief Scientist Mallick Parag

      4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

      3/4/25 4:51:51 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4 filed by CEO, President, and Secretary Patel Sujal M

      4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

      3/4/25 4:51:39 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4 filed by Senior VP, Product Development Sankar Subramanian

      4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

      3/4/25 4:51:29 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Senior VP, Operations Godwin Mary E. exercised 47,031 shares at a strike of $0.46 and sold $134,744 worth of shares (47,031 units at $2.87) (SEC Form 4)

      4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

      9/25/24 6:29:21 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    Nautilus Biotechnolgy Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Nautilus Biotechnology downgraded by Goldman with a new price target

      Goldman downgraded Nautilus Biotechnology from Neutral to Sell and set a new price target of $1.75

      12/5/24 7:46:35 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Guggenheim initiated coverage on Nautilus Biotechnology with a new price target

      Guggenheim initiated coverage of Nautilus Biotechnology with a rating of Buy and set a new price target of $6.00

      6/27/24 7:49:37 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Jefferies resumed coverage on Nautilus Biotechnology with a new price target

      Jefferies resumed coverage of Nautilus Biotechnology with a rating of Hold and set a new price target of $3.00

      6/3/24 8:53:10 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Morgan Stanley initiated coverage on Nautilus Biotechnology with a new price target

      Morgan Stanley initiated coverage of Nautilus Biotechnology with a rating of Equal-Weight and set a new price target of $8.00

      1/6/22 5:56:03 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cowen & Co. initiated coverage on Nautilus Biotechnology

      Cowen & Co. initiated coverage of Nautilus Biotechnology with a rating of Outperform

      11/2/21 7:05:00 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Goldman Sachs initiated coverage on Nautilus Biotechnology with a new price target

      Goldman Sachs initiated coverage of Nautilus Biotechnology with a rating of Neutral and set a new price target of $10.00

      8/4/21 5:01:56 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Jefferies initiated coverage on Nautilus Biotechnology with a new price target

      Jefferies initiated coverage of Nautilus Biotechnology with a rating of Buy and set a new price target of $13.00

      7/13/21 6:30:05 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    Nautilus Biotechnolgy Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Nautilus Biotechnolgy Inc.

      SC 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)

      11/14/24 4:31:50 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13D/A filed by Nautilus Biotechnolgy Inc. (Amendment)

      SC 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)

      11/16/23 9:18:26 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13D/A filed by Nautilus Biotechnolgy Inc. (Amendment)

      SC 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)

      3/1/23 3:30:45 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Nautilus Biotechnolgy Inc.

      SC 13G - Nautilus Biotechnology, Inc. (0001808805) (Subject)

      2/13/23 4:15:52 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Nautilus Biotechnolgy Inc. (Amendment)

      SC 13G/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)

      2/14/22 4:11:50 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Nautilus Biotechnolgy Inc.

      SC 13G - Nautilus Biotechnology, Inc. (0001808805) (Subject)

      2/10/22 4:19:31 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13D filed by Nautilus Biotechnolgy Inc.

      SC 13D - Nautilus Biotechnology, Inc. (0001808805) (Subject)

      8/25/21 8:58:04 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    Nautilus Biotechnolgy Inc. SEC Filings

    See more
    • Nautilus Biotechnolgy Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Nautilus Biotechnology, Inc. (0001808805) (Filer)

      5/2/25 4:30:28 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEFA14A filed by Nautilus Biotechnolgy Inc.

      DEFA14A - Nautilus Biotechnology, Inc. (0001808805) (Filer)

      4/29/25 4:07:31 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEF 14A filed by Nautilus Biotechnolgy Inc.

      DEF 14A - Nautilus Biotechnology, Inc. (0001808805) (Filer)

      4/29/25 4:06:20 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 10-Q filed by Nautilus Biotechnolgy Inc.

      10-Q - Nautilus Biotechnology, Inc. (0001808805) (Filer)

      4/29/25 4:05:12 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Nautilus Biotechnolgy Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Nautilus Biotechnology, Inc. (0001808805) (Filer)

      4/28/25 6:12:35 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SCHEDULE 13D/A filed by Nautilus Biotechnolgy Inc.

      SCHEDULE 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)

      3/5/25 4:54:27 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form S-8 filed by Nautilus Biotechnolgy Inc.

      S-8 - Nautilus Biotechnology, Inc. (0001808805) (Filer)

      2/27/25 4:52:21 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 10-K filed by Nautilus Biotechnolgy Inc.

      10-K - Nautilus Biotechnology, Inc. (0001808805) (Filer)

      2/27/25 4:46:48 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SCHEDULE 13D/A filed by Nautilus Biotechnolgy Inc.

      SCHEDULE 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)

      1/31/25 9:06:27 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Nautilus Biotechnolgy Inc. filed SEC Form 8-K: Leadership Update

      8-K - Nautilus Biotechnology, Inc. (0001808805) (Filer)

      1/31/25 5:15:22 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    Nautilus Biotechnolgy Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nautilus Biotechnology Reports First Quarter 2025 Financial Results

      SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2025. "In Q1, we saw continued development progress based on the results of internal verification and validation work we've done on our Tau proteoform assay," said Sujal Patel, CEO of Nautilus Biotechnology. "The assay's reproducibility, accuracy, dynamic range, and sample compatibility align closely with our anticipated launch specifications and with the requirements we continue to hear from potential customers and partners. We are confident that 202

      4/29/25 8:00:00 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Nautilus Biotechnology to Announce First Quarter 2025 Financial Results on April 29, 2025

      SEATTLE, April 16, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule proteome analysis platform, today announced it will report financial results for the first quarter 2025 before market open on Tuesday, April 29, 2025. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle, Washington and it

      4/16/25 8:00:00 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2024 Financial Results

      SEATTLE, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2024. Reported total operating expenses for the fourth quarter of 2024 were $20.0 million, roughly equal to the fourth quarter of 2023, and $0.9 million above last quarter reflecting an ongoing focus on expense management;Announced an expectation that the launch of Nautilus' proteome analysis platform - instruments and reagents - will occur in late 2026;Announced a reduction in headcount of approximately 16% in order to appropriat

      2/27/25 8:00:00 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Nautilus Biotechnology to Participate in the TD Cowen 45th Annual Healthcare Conference

      SEATTLE, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the TD Cowen 45th Annual Healthcare Conference. Nautilus' management is scheduled to participate in a fireside chat on Monday, March 3, 2025, at 1:50 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle and its research and development headquarters in

      2/18/25 8:00:00 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

      SEATTLE, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the fourth quarter and full year of 2024 before market open on Thursday, February 27, 2025. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattl

      2/6/25 8:00:00 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research's Distinguished Investigator Award

      SEATTLE, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced Nautilus co-founder and Chief Scientist Parag Mallick, Ph.D., was bestowed the 2024 Distinguished Investigator (DI) Award by the Academy for Radiology and Biomedical Imaging Research (the Academy). The Award recognizes Dr. Mallick's notable achievements in the field of imaging research, including his decades-long leadership, high-impact publications, and ongoing research and development contributions. "Innovation in imaging science is essential for advancing biomedicine

      10/31/24 8:00:00 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Nautilus Biotechnology to Participate in the Inaugural Guggenheim Healthcare Conference

      SEATTLE, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the Inaugural Guggenheim Healthcare Conference. Nautilus' management is scheduled to participate in a fireside chat on Wednesday, November 13, 2024, at 9:30 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Ca

      10/30/24 8:00:00 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Nautilus Biotechnology Reports Third Quarter 2024 Financial Results

      SEATTLE, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2024. "I'm excited about the expanding opportunity I see for proteomics and am pleased with the progress we're making as a business," said Sujal Patel, CEO of Nautilus. "We consistently receive positive feedback from researchers around the world as they tell us of their desire to explore the proteome more deeply and more broadly, and of the significant limitations of what's currently available. It is becoming ever more apparent that they understand

      10/29/24 8:00:00 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Nautilus Biotechnology to Announce Third Quarter 2024 Financial Results on October 29, 2024

      SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the third quarter 2024 before market open on Tuesday, October 29, 2024. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle, Washington and i

      10/8/24 8:00:00 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Nautilus Biotechnology Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer

      SEATTLE, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform for comprehensively quantifying the proteome, today announced the appointment of Kentaro (Ken) Suzuki as Chief Marketing Officer. Mr. Suzuki joins Nautilus after 25 years in product and marketing leadership roles at Agilent Technologies, most recently serving as Vice President and General Manager of Agilent's Mass Spectrometry division. He has held numerous leadership positions at Agilent, including in the Strategic Program Office and Certified Pre-Owned Instruments, CrossLab Services and Support, and Spectroscopy. "Ke

      9/17/24 8:00:00 AM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    Nautilus Biotechnolgy Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO, President, and Secretary Patel Sujal M bought $76,918 worth of shares (77,233 units at $1.00), increasing direct ownership by 0.77% to 10,141,721 units (SEC Form 4)

      4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

      3/21/25 4:44:37 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Patel Sujal M bought $41,478 worth of shares (14,474 units at $2.87), increasing direct ownership by 0.14% to 10,064,488 units (SEC Form 4)

      4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

      3/11/24 8:21:59 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Patel Sujal M bought $99,054 worth of shares (35,526 units at $2.79), increasing direct ownership by 0.35% to 10,050,014 units (SEC Form 4)

      4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

      3/7/24 7:06:49 PM ET
      $NAUT
      Biotechnology: Laboratory Analytical Instruments
      Industrials